As a class, IMiDs have a wide range of biological activities such as inhibition of NF-kB and interferon regulatory factor 4 (IRF4), increased expression of pro-apoptotic factors such as Caspase-8, and downregulation of angiogenesis via VEGF and IL-6 production leading to a disruption of the myeloma cell-marrow microenvironment interaction [8,9,10,11]. This evidence concerns the gene IRF4 and plasma cell myeloma.